About

Dr. Lee Nguyen is an infectious diseases pharmacist with a passion for antimicrobial stewardship and pharmacy education. He established an antimicrobial stewardship program at St. Jude Medical Center years prior to regulatory requirements mandating the change. The program was one of the first to be spotlighted by the California Department of Public Health’s Antimicrobial Stewardship Program Project and he has served as a mentor to other hospitals developing their stewardship programs. Dr. Nguyen is able to merge his two passions of pharmacy education and antimicrobials stewardship by including relevant clinical cases in his courses and through mentorship in quality improvement/research projects related to antimicrobials. He and his students have presented outcomes-based research at national and international infectious diseases meetings. In addition to student mentorship, Dr. Nguyen has mentored pharmacy practice residents on their research projects as well as provided guidance as the academic residency coordinator. His research interests include infectious diseases, antimicrobial stewardship, clinical pharmacy, evidence-based practice, outcomes research, and resistance.

Research topics

• Medicine
• Computer Science
• Political Science
• Microbiology
• Pediatrics
• Emergency medicine
• Environmental health
• Risk analysis (engineering)
• Nursing
• Internal medicine
• Biology
• Physical therapy
• Immunology
• Intensive care medicine
• Demography
• Economic growth

Selected publications

• Disparities in Pain Management

  Anesthesiology Clinics · 2023 · 36 citations

  1st authorCorresponding
  • Medicine
  • Nursing
  • Physical therapy
  DOI

• Current and recommended practices for evaluating adverse drug events using electronic health records: A systematic review

  JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · 2021 · 7 citations

  • Computer Science
  • Medicine
  • Family medicine

  Abstract Electronic health records (EHR) are widely used sources of real‐world data in pharmacoepidemiologic research. As there is no end‐to‐end guidance for generating medication safety evidence with EHR, this study conducted a systematic review to determine the current and recommended practices in the literature. PubMed, Scopus, and CINAHL were searched for English articles published between 1 January 2010 and 11 June 2020. Selected articles were published in peer‐reviewed journals, conducted in the United States, analyzed structured EHR data, and defined drug exposure and adverse drug events (ADEs). The study evaluated methodological quality with a modified Newcastle‐Ottawa Scale (NOS) score ranging from 0 to 9 points. Data synthesis was performed with thematic analysis. Twenty‐six from 3885 articles were selected. The majority were cohort studies (85%). The studies were well designed, with a median NOS score of 9. Drug exposure was defined with dispensing (58%) and prescribing (31%) records. ADEs were defined across five categories: diagnosis codes (77%), validated outcome algorithms (35%), objective measures (35%), treatment procedures (19%), and antidotes (2%). Common covariates were age (89%), gender (85%), comorbidities (81%), and medication‐co‐medication use (73%). Four studies (15%) empirically defined covariates in a data‐driven manner. Twenty‐two (85%) analyzed covariates as confounders or effect modifiers in their analyses. Results were analyzed with either intention‐to‐treat (73%) or as‐treated (39%) approaches. Key recommendations include selecting dispensing rather than prescribing records, considering a proxy date of dispensation where applicable, selecting new instead of prevalent drug users, improving adoption of validated outcome algorithms, and not utilizing objective measures as the primary indicator of ADEs.

  PublisherDOI

• The antibiogram: key considerations for its development and utilization

  JAC-Antimicrobial Resistance · 2021 · 114 citations

  • Computer Science
  • Intensive care medicine
  • Political Science

  The antibiogram is an essential resource for institutions to track changes in antimicrobial resistance and to guide empirical antimicrobial therapy. In this Viewpoint, data and examples from literature are presented that suggest institutions have not completely adopted the standardized approach in developing antibiograms, as variations in the development methodologies of antibiograms exist despite consensus guidelines (M39) published by CLSI. We emphasize developing antibiograms in line with the M39 recommendations will help ensure that they are accurate, reliable and valid, and highlight that understanding the limitations of antibiogram data is critical to ensuring appropriate interpretation and application to clinical decision-making. We also stress the importance of easy accessibility and education on antibiogram use, to allow for prescribers to select the most optimal empirical treatment regimens and propose the creation of an abbreviated antibiogram for frontline users. Multidisciplinary antimicrobial stewardship programmes are vital to accomplishing these goals.

  DOI

• Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Laboratory in Northern Orange County, California

  Journal of Racial and Ethnic Health Disparities · 2020 · 6 citations

  Senior authorCorresponding
  • Medicine
  • Pediatrics
  • Emergency medicine

  INTRODUCTION: The severe acute respiratory syndrome related coronavirus 2 (SARS-CoV-2) has infected more than 20 million people worldwide, and the spread is most prevalent in the USA, where California had accounted over 240,000 cases in the initial 5 months of the pandemic. To estimate the number of infected persons in our community, we conducted a cross-sectional study to estimate seroprevalence of SARS-CoV-2 infection. METHODS: This cross-sectional study evaluated the presence of immunoglobulin G, antibody for SARS-CoV-2 during the time period of July 15, 2020, to July 27, 2020. Testing was done on serum samples from patients who had visited affiliated outpatient clinics or our emergency department. Additionally, we collected age, gender, ethnicity, race, and location of testing. RESULTS: Eight hundred sixty-five tests were included in the study. The outpatient clinics cohort accounted for 56% of results and emergency department (ED) contributed 44%. The positive percentage of SARS-CoV-2 test was 9.4% (95% CI: 0.08-0.12). The positivity rates of the outpatient (5.6%) and ED (14.2%) setting differed. The prevalence of SARS-CoV-2 IgG was greatest in those that identified as Hispanic/Latino, 18.1% versus 13.4% in other groups. Specifically compared to the non-Hispanic/Latino population, the prevalence was significantly higher, with a relative risk of 2.73 (95% CI: 1.8-4.1), p < 0.0001. CONCLUSION: The low antibody positivity rate in the community indicates the need for a vaccine. The Hispanic/Latino patient population should be considered for increased education on preventing transmission and acquisition of COVID-19 as well as being considered as a priority for vaccination once a vaccine is available.

  DOI

Frequent coauthors

• Harry Peled

  Bridgepoint (United Kingdom)

  9 shared

• Kim S. Smith

  Imperial College London

  9 shared

• Mina Firoozi

  St. Jude Medical Center

  9 shared

• David Park

  Bellevue Hospital Center

  9 shared

• Sajen Mathews

  St. Jude Medical Center

  9 shared

• Jason Yamaki

  Hoag Memorial Hospital Presbyterian

  7 shared

• Paul Gavaza

  Loma Linda University

  4 shared

• Nimish Patel

  4 shared

Awards & honors

• Favorite Professor Quote Award (2016), Loma Linda University…
• Favorite Professor Quote Award (2015), Loma Linda University…
• Preceptor of the Year (2009), Loma Linda University School o…

Similar researchers at University of California, Irvine

• Simin Liuh-187
• Simona Murgiah-181
• Donald R. Blakeh-144
• Eric Rignoth-143
• Alex B Guentherh-131